E-resources
-
Loflin, Mallory J.E.; Kiluk, Brian D.; Huestis, Marilyn A.; Aklin, Will M.; Budney, Alan J.; Carroll, Kathleen M.; D'Souza, Deepak Cyril; Dworkin, Robert H.; Gray, Kevin M.; Hasin, Deborah S.; Lee, Dustin C.; Le Foll, Bernard; Levin, Frances R.; Lile, Joshua A.; Mason, Barbara J.; McRae-Clark, Aimee L.; Montoya, Ivan; Peters, Erica N.; Ramey, Tatiana; Turk, Dennis C.; Vandrey, Ryan; Weiss, Roger D.; Strain, Eric C.
Drug and alcohol dependence, 07/2020, Volume: 212Journal Article
•Provides a review of clinical outcome assessments for CUD trial endpoints.•Abstinence is not the only valid indicator of CUD treatment success.•A core toolkit of assessments for CUD treatment studies is needed. There is considerable variability in the use of outcome measures in clinical trials for cannabis use disorder (CUD), and a lack of consensus regarding optimal outcomes may have hindered development and approval of new pharmacotherapies. The goal of this paper is to summarize an evaluation of assessment measures and clinical endpoints for CUD clinical trials, and propose a research agenda and priorities to improve CUD clinical outcome assessments. The primary recommendation is that sustained abstinence from cannabis should not be considered the primary outcome for all CUD clinical trials as it has multiple limitations. However, there are multiple challenges to the development of a reliable and valid indicator of cannabis reduction, including the lack of a standard unit of measure for the various forms of cannabis and products and the limitations of currently available biological and self-report assessments. Development of a core toolkit of assessments is needed to both allow flexibility for study design, while facilitating interpretation of outcomes across trials. Four primary agenda items for future research are identified to expedite development of improved clinical outcome assessments for this toolkit: (1) determine whether minimally invasive biologic assays could identify an acute level of cannabis use associated with psychomotor impairment or other cannabis-related harms; (2) create an indicator of quantity of cannabis use that is consistent across product types; (3) examine the presence of cannabis-specific functional outcomes; and (4) identify an optimal duration to assess changes in CUD diagnostic criteria.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.